JAK1 and uveitis: Brepocitnib is a selective JAK1 and tyrosine kinase 2 (TYK2) inhibitor that is under evaluation in a multi-centre Phase III clinical trial (NCT06431373) to determine efficacy in treatment of non-anterior non-infectious uveitis after a Phase II trial (NCT05523765) demonstrated a dose-dependent treatment benefit and was accordingly granted Fast Track Designation by the FDA.